Taiwan
· Delayed Price · Currency is TWD OBI Pharma Statistics
Total Valuation
OBI Pharma has a market cap or net worth of TWD 10.08 billion. The enterprise value is 9.08 billion.
| Market Cap | 10.08B |
| Enterprise Value | 9.08B |
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OBI Pharma has 262.97 million shares outstanding. The number of shares has increased by 5.59% in one year.
| Current Share Class | 262.97M |
| Shares Outstanding | 262.97M |
| Shares Change (YoY) | +5.59% |
| Shares Change (QoQ) | +10.23% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 5.16% |
| Float | 200.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 148.30 |
| PB Ratio | 2.36 |
| P/TBV Ratio | 3.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.95 |
| EV / Sales | 133.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.40 |
Financial Position
The company has a current ratio of 12.64, with a Debt / Equity ratio of 0.11.
| Current Ratio | 12.64 |
| Quick Ratio | 11.32 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.23 |
| Interest Coverage | -215.71 |
Financial Efficiency
Return on equity (ROE) is -57.04% and return on invested capital (ROIC) is -29.78%.
| Return on Equity (ROE) | -57.04% |
| Return on Assets (ROA) | -29.11% |
| Return on Invested Capital (ROIC) | -29.78% |
| Return on Capital Employed (ROCE) | -49.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | 4.86 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.48% in the last 52 weeks. The beta is 0.53, so OBI Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | -37.48% |
| 50-Day Moving Average | 50.98 |
| 200-Day Moving Average | 62.22 |
| Relative Strength Index (RSI) | 32.44 |
| Average Volume (20 Days) | 1,685,181 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OBI Pharma had revenue of TWD 68.00 million and -2.30 billion in losses. Loss per share was -9.50.
| Revenue | 68.00M |
| Gross Profit | -66.29M |
| Operating Income | -2.31B |
| Pretax Income | -2.48B |
| Net Income | -2.30B |
| EBITDA | -2.14B |
| EBIT | -2.31B |
| Loss Per Share | -9.50 |
Balance Sheet
The company has 2.45 billion in cash and 473.77 million in debt, giving a net cash position of 1.98 billion or 7.53 per share.
| Cash & Cash Equivalents | 2.45B |
| Total Debt | 473.77M |
| Net Cash | 1.98B |
| Net Cash Per Share | 7.53 |
| Equity (Book Value) | 4.28B |
| Book Value Per Share | 12.60 |
| Working Capital | 2.55B |
Cash Flow
In the last 12 months, operating cash flow was -1.98 billion and capital expenditures -79.59 million, giving a free cash flow of -2.06 billion.
| Operating Cash Flow | -1.98B |
| Capital Expenditures | -79.59M |
| Free Cash Flow | -2.06B |
| FCF Per Share | -7.84 |
Margins
| Gross Margin | -97.48% |
| Operating Margin | -3,400.51% |
| Pretax Margin | -3,645.07% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OBI Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.59% |
| Shareholder Yield | -5.59% |
| Earnings Yield | -22.80% |
| FCF Yield | -20.45% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |